Lung Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022

Published on : Jul-2017 | List of Tables : 236 | List of Figures : 68 | No. of Pages : 170 | Report Code : FACT49MR | Format : ppt pdf Excel Word

Lung cancer or lung carcinoma is malignant maturation of lung tumor, caused by uncontrolled growth of cells & tissues in the lung. Lung cancer diagnostics can be defined as an umbrella of tests & diagnosis procedures used in treatment of lung cancer, which includes methods such as imaging, tumor screening, sputum cytology tests, and biopsy.

Fact.MR, in its recent report, estimates the global lung cancer diagnostics market to register an impressive 7.3% CAGR during the forecast period 2017 to 2022.

The growth of the global market for lung cancer diagnostics is primarily attributed to increasing developments in lung cancer-specific biomarkers. These diagnostic tools are expected to facilitate personalized treatment approach towards lung malignancies. A number of biomarkers exist in the research pipeline. In the recent past, Epigenomics AG launched a new test based on blood utilizing DNA methylation biomarkers, whose developments are in the process. The initial results obtained from these tests have promised early diagnosis of lung cancer. Such incidences are expected to increase demand for lung cancer diagnostics across the globe.

Increasing Awareness Programs for Lung Cancer to Drive Growth of the Market

A number of awareness programs associated with lung cancer and its related symptoms have been initiated in order to enhance the diagnosis and screening rates of individuals with high risks of developing lung malignancies. For example – In the United Kingdom, November is considered to be the lung cancer awareness month, and is supported by Roy Castle Lung Cancer Foundation. Such initiatives help in raising awareness about early detection and diagnosis of lung cancer.

CA tests will continue to be the most lucrative tests for lung cancer diagnostics in the market. Revenue from CA tests will account for US$ 889.3 Mn by 2022-end. Angiogenesis inhibitor is expected to witness the fastest expansion among test type in the market, followed by HER 2 tests. Revenue from ALK tests for lung cancer diagnostics will continue to remain low in the market.

Market Taxonomy

Test Type

End User

Indication

CA Test

Hospital Associated Labs

Non Small-cell Lung Cancer

HER2 Tests

Independent Diagnostic Laboratories

Small-cell Lung Cancer

ALK Tests

Cancer Research Institutes

 

Angiogenesis Inhibitor

Others

 

EGFR Mutation Tests

   

KRAS Mutation Tests

   

Others

   

(Additional information, including cross-sectional data and country-wise analysis & forecast is available in the report)

Hospital-associated Labs to Remain the Most Lucrative End-Users of Lung Cancer Diagnostics

Hospital-associated labs will remain the most lucrative end-users of lung cancer diagnostics in the global market, with revenues estimated to reach nearly US$ 1,500 Mn by 2022-end. Cancer research institutes will continue to exhibit the fastest expansion in the global lung cancer diagnostics market, followed by independent diagnostic laboratories. In addition, independent diagnostic laboratories are expected to be the second largest end-users of lung cancer diagnostics throughout the forecast period.

On the basis of indication, although non-small cell lung cancer is expected to remain sought-after in the market, small cell-lung cancer is expected to exhibit the fastest expansion through 2022. Revenue from non-small cell lung cancer is expected to remain largest during the forecast period. In contrast, revenue from small cell lung cancer will continue to be low in the global lung cancer diagnostics market.

Competition Tracking

Novel product launches for lung cancer diagnostics is a key strategy adopted by leading players in the global market, in order to increase their product portfolio. Fact.MR’s report profiles key market players, which include Illumina, Inc., Abbott Laboratories, Thermo Fischer Scientific, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, NeoGenomics Laboratories, Inc., NanoString Technologies, Inc., Myriad Genetics, Inc., Roche Holding AG, and Danaher Corporation.

Note: The insights mentioned here are of the respective analysts, and do not reflect the position of Fact.MR

Medical organizations as well as leaders in the global pharmaceuticals industry are stepping up their efforts towards development of profound diagnosis for lung cancer. Rising number of deaths caused by lung cancer is taking a toll on governments as people are demanding precision diagnosis and a cure-all for this terminal disease. In a bid to adapt to the urban rat race, millions of consumers have adopted lifestyles that are stemming the occurrence of lung cancer. For public administration authorities, compelling people to avoid such lifestyles is like challenging the status quo. The burden of controlling the incidence of lung cancer gets passed on to hospitals & medical research organizations as they strive to develop novel diagnostic and therapeutic procedures.

The report on the global market for lung cancer discusses such key factors that govern the economics of lung cancer diagnostics across the globe. Some of the key influences for the growth of global lung cancer diagnostics market include:

  • rising presence of carcinogenic elements in common consumables
  • surging exposure to toxic substances in factories & industrial settings
  • lack of awareness related to causes, symptoms, and preventive measures for lung cancer
  • high healthcare costs, deterring lung cancer patients from seeking optimum diagnosis

With growing incidence of lung cancer, the future generations will witness a more accessible, affordable, and diagnosis-associated treatment for lung cancer. As lung cancer research organizations & societies struggle to develop effective medications in tight-budgeted capitals, governments are deploying initiatives that boost the awareness of lung cancer.

Need for Premeditated Lung Cancer Patient Compliance 

Lung cancer patients are often riddled with confusing options for diagnosis. Choosing the right screening test can become a dilemma for the patient and his/her family. Companies manufacturing medical instruments and devices for diagnosis of lung cancer are expected to mitigate such difficulties by facilitating a well-laid patient compliance regime.

The global market for lung cancer diagnostics is anticipated to witness significant impact from diagnosis-associated patient compliance trials. Positive attitudes of patients towards certain diagnosis alternatives is decisive in changing future undertakings. Prominent diagnostic tools are likely to be replaced with their upgraded variants. The report has highlighted the influence of government undertakings in offering a better compliance for diagnosis of lung cancer patients.

Key players in the global lung cancer diagnostics market are collaborating with regional health ministries and medical administrators for gauging the impact of therapeutic diagnosis on lung cancer patients. Such cooperative efforts are of paramount importance in the global lung cancer diagnostics market, where overlooking the plausible aftereffects of diagnostic procedures can cost lives.

Lung Cancer diagnostics market – Regional Overview & Competitive Backdrop

A comprehensive section on the regional analysis of global lung cancer diagnostics market is included in the report. North America, Europe, Japan, Asia-Pacific excluding Japan (APEJ), Latin America, and Middle East & Africa are key regions into which the expansion of global lung cancer diagnostics market is studied. Developed markets with robust healthcare infrastructures are deemed lucrative for patients seeking diagnosis for lung cancer. On the other hand, higher resource availability, cheap wages, and lenient manufacturing regulations in developing regions attract the attention of manufacturers of lung cancer diagnosis instruments.

In the report, there is an elaborate section on the competitive landscape of global lung cancer diagnostics market. This part profiles key players in the global market, which includes leading manufacturers of diagnostic devices and related medical apparatus. The scalability employed in profiling these players includes criteria such as the company’s contribution to global lung cancer diagnostics market revenues, recent mergers & acquisitions involving the company, and new product launches. Through this report, companies can also understand the investment standpoint in the global lung cancer diagnostics market, which can be further inferred while taking insightful actions.

Research Methodology

Fact.MR is committed to offer unbiased and independent market research solutions to its clients. Each market report of Fact.MR is compiled after months of exhaustive research. We bank on a mix of tried-and-tested and innovative research methodologies to offer the most comprehensive and accurate information. Our main sources of research include,

  • Primary research
  • Secondary research
  • Trade research
  • Focused interviews
  • Social media analysis

Chapter 1. Global Lung Cancer Diagnostics Market - Executive Summary. 12

Chapter 2. Global Lung Cancer Diagnostics Market Overview. 14
2.1. Introduction. 14
       2.1.1. Global Lung Cancer Diagnostics Market Taxonomy. 14
       2.1.2. Global Lung Cancer Diagnostics Market Definition. 14
2.2. Global Lung Cancer Diagnostics Market Size (US$ Mn) and Forecast, 2012-2022. 15
       2.2.1. Global Lung Cancer Diagnostics Market Y-o-Y Growth. 15
2.3. Global Lung Cancer Diagnostics Market Dynamics. 15
       2.3.1. Drivers. 15
       2.3.2. Restraints. 15
       2.3.3. Trends. 16
2.4. Supply Chain. 16
2.5. Key Participants Market Presence (Intensity Map) By Region. 16

Chapter 3. Global Lung Cancer Diagnostics Market Analysis and Forecast By Test Type. 17
3.1. Global Lung Cancer Diagnostics Market Size and Forecast By Test Type, 2012-2022. 17
       3.1.1. CA Test Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 17
                3.1.1.1. Revenue (US$ Mn) Comparison, By Region. 17
                3.1.1.2. Market Share Comparison, By Region. 19
                3.1.1.3. Y-o-Y growth Comparison, By Region. 19
       3.1.2. HER2 Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 20
                3.1.2.1. Revenue (US$ Mn) Comparison, By Region. 20
                3.1.2.2. Market Share Comparison, By Region. 22
                3.1.2.3. Y-o-Y growth Comparison, By Region. 22
       3.1.3. ALK Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 23
                3.1.3.1. Revenue (US$ Mn) Comparison, By Region. 23
                3.1.3.2. Market Share Comparison, By Region. 25
                3.1.3.3. Y-o-Y growth Comparison, By Region. 25
       3.1.4. Angiogenesis Inhibitor Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 26
                3.1.4.1. Revenue (US$ Mn) Comparison, By Region. 26
                3.1.4.2. Market Share Comparison, By Region. 28
                3.1.4.3. Y-o-Y growth Comparison, By Region. 28
       3.1.5. EGFR Mutation Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 29
                3.1.5.1. Revenue (US$ Mn) Comparison, By Region. 29
                3.1.5.2. Market Share Comparison, By Region. 31
                3.1.5.3. Y-o-Y growth Comparison, By Region. 31
       3.1.6. KRAS Mutation Tests Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 32
                3.1.6.1. Revenue (US$ Mn) Comparison, By Region. 32
                3.1.6.2. Market Share Comparison, By Region. 34
                3.1.6.3. Y-o-Y growth Comparison, By Region. 34
       3.1.7. Others Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 35
                3.1.7.1. Revenue (US$ Mn) Comparison, By Region. 35
                3.1.7.2. Market Share Comparison, By Region. 37
                3.1.7.3. Y-o-Y growth Comparison, By Region. 37

Chapter 4. Global Lung Cancer Diagnostics Market Analysis and Forecast By End User. 39
4.1. Global Lung Cancer Diagnostics Market Size and Forecast By End User, 2012-2022. 39
       4.1.1. Hospital Associated Labs Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 39
                4.1.1.1. Revenue (US$ Mn) Comparison, By Region. 39
                4.1.1.2. Market Share Comparison, By Region. 41
                4.1.1.3. Y-o-Y growth Comparison, By Region. 41
       4.1.2. Independent Diagnostic Laboratories Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 42
                4.1.2.1. Revenue (US$ Mn) Comparison, By Region. 42
                4.1.2.2. Market Share Comparison, By Region. 44
                4.1.2.3. Y-o-Y growth Comparison, By Region. 44
       4.1.3. Cancer Research Institutes Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 45
                4.1.3.1. Revenue (US$ Mn) Comparison, By Region. 45
                4.1.3.2. Market Share Comparison, By Region. 47
                4.1.3.3. Y-o-Y growth Comparison, By Region. 47
       4.1.4. Others Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 48
                4.1.4.1. Revenue (US$ Mn) Comparison, By Region. 48
                4.1.4.2. Market Share Comparison, By Region. 50
                4.1.4.3. Y-o-Y growth Comparison, By Region. 50

Chapter 5. Global Lung Cancer Diagnostics Market Analysis and Forecast By Indication. 52
5.1. Global Lung Cancer Diagnostics Market Size and Forecast By Indication, 2012-2022. 52
       5.1.1. Non Small-cell Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 52
                5.1.1.1. Revenue (US$ Mn) Comparison, By Region. 52
                5.1.1.2. Market Share Comparison, By Region. 54
                5.1.1.3. Y-o-Y growth Comparison, By Region. 54
       5.1.2. Small-cell Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 55
                5.1.2.1. Revenue (US$ Mn) Comparison, By Region. 55
                5.1.2.2. Market Share Comparison, By Region. 57
                5.1.2.3. Y-o-Y growth Comparison, By Region. 57

Chapter 6. Global Lung Cancer Diagnostics Market Analysis and Forecast By Region. 59
6.1. Global Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 59
       6.1.1. North America Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 59
                6.1.1.1. Revenue (US$ Mn) Comparison, By Test Type. 59
                6.1.1.2. Revenue (US$ Mn) Comparison, By End User. 61
                6.1.1.3. Revenue (US$ Mn) Comparison, By Indication. 62
       6.1.2. Latin America Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 64
                6.1.2.1. Revenue (US$ Mn) Comparison, By Test Type. 64
                6.1.2.2. Revenue (US$ Mn) Comparison, By Indication. 67
       6.1.3. Europe Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 69
                6.1.3.1. Revenue (US$ Mn) Comparison, By Test Type. 69
                6.1.3.2. Revenue (US$ Mn) Comparison, By End User. 71
                6.1.3.3. Revenue (US$ Mn) Comparison, By Indication. 72
       6.1.4. Japan Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 74
                6.1.4.1. Revenue (US$ Mn) Comparison, By Test Type. 74
                6.1.4.2. Revenue (US$ Mn) Comparison, By Indication. 77
       6.1.5. APEJ Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 79
                6.1.5.1. Revenue (US$ Mn) Comparison, By Test Type. 79
                6.1.5.2. Revenue (US$ Mn) Comparison, By End User. 81
                6.1.5.3. Revenue (US$ Mn) Comparison, By Indication. 82
       6.1.6. MEA Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 84
                6.1.6.1. Revenue (US$ Mn) Comparison, By Test Type. 84
                6.1.6.2. Revenue (US$ Mn) Comparison, By End User. 86
                6.1.6.3. Revenue (US$ Mn) Comparison, By Indication. 87

Chapter 7. North America Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 90
7.1. US Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 90
       7.1.1. Revenue (US$ Mn) Comparison, By Test Type. 90
       7.1.2. Revenue (US$ Mn) Comparison, By End User. 91
       7.1.3. Revenue (US$ Mn) Comparison, By Indication. 91
7.2. Canada Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 92
       7.2.1. Revenue (US$ Mn) Comparison, By Test Type. 92
       7.2.2. Revenue (US$ Mn) Comparison, By End User. 93
       7.2.3. Revenue (US$ Mn) Comparison, By Indication. 94

Chapter 8. Latin America Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 96
8.1. Brazil Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 96
       8.1.1. Revenue (US$ Mn) Comparison, By Test Type. 96
       8.1.2. Revenue (US$ Mn) Comparison, By End User. 97
       8.1.3. Revenue (US$ Mn) Comparison, By Indication. 97
8.2. Mexico Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 98
       8.2.1. Revenue (US$ Mn) Comparison, By Test Type. 98
       8.2.2. Revenue (US$ Mn) Comparison, By End User. 99
       8.2.3. Revenue (US$ Mn) Comparison, By Indication. 100
8.3. Argentina Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 101
       8.3.1. Revenue (US$ Mn) Comparison, By Test Type. 101
       8.3.2. Revenue (US$ Mn) Comparison, By End User. 102
       8.3.3. Revenue (US$ Mn) Comparison, By Indication. 103

Chapter 9. Europe Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 104
9.1. Germany Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 104
       9.1.1. Revenue (US$ Mn) Comparison, By Test Type. 104
       9.1.2. Revenue (US$ Mn) Comparison, By End User. 105
       9.1.3. Revenue (US$ Mn) Comparison, By Indication. 106
9.2. UK Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 106
       9.2.1. Revenue (US$ Mn) Comparison, By Test Type. 106
       9.2.2. Revenue (US$ Mn) Comparison, By End User. 107
       9.2.3. Revenue (US$ Mn) Comparison, By Indication. 108
9.3. France Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 109
       9.3.1. Revenue (US$ Mn) Comparison, By Test Type. 109
       9.3.2. Revenue (US$ Mn) Comparison, By End User. 110
       9.3.3. Revenue (US$ Mn) Comparison, By Indication. 111
9.4. Spain Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 111
       9.4.1. Revenue (US$ Mn) Comparison, By Test Type. 111
       9.4.2. Revenue (US$ Mn) Comparison, By End User. 112
       9.4.3. Revenue (US$ Mn) Comparison, By Indication. 113
9.5. Italy Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 114
       9.5.1. Revenue (US$ Mn) Comparison, By Test Type. 114
       9.5.2. Revenue (US$ Mn) Comparison, By End User. 115
       9.5.3. Revenue (US$ Mn) Comparison, By Indication. 116
9.6. Nordic Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 116
       9.6.1. Revenue (US$ Mn) Comparison, By Test Type. 116
       9.6.2. Revenue (US$ Mn) Comparison, By End User. 117
       9.6.3. Revenue (US$ Mn) Comparison, By Indication. 118

Chapter 10. Japan Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 120
10.1. Japan  Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 120
       10.1.1. Revenue (US$ Mn) Comparison, By Test Type. 120
       10.1.2. Revenue (US$ Mn) Comparison, By End User. 121
       10.1.3. Revenue (US$ Mn) Comparison, By Indication. 121

Chapter 11. APEJ Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 123
11.1. China Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 123
       11.1.1. Revenue (US$ Mn) Comparison, By Test Type. 123
       11.1.2. Revenue (US$ Mn) Comparison, By End User. 124
       11.1.3. Revenue (US$ Mn) Comparison, By Indication. 124
11.2. India Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 125
       11.2.1. Revenue (US$ Mn) Comparison, By Test Type. 125
       11.2.2. Revenue (US$ Mn) Comparison, By End User. 126
       11.2.3. Revenue (US$ Mn) Comparison, By Indication. 127
11.3. Malaysia Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 128
       11.3.1. Revenue (US$ Mn) Comparison, By Test Type. 128
       11.3.2. Revenue (US$ Mn) Comparison, By End User. 129
       11.3.3. Revenue (US$ Mn) Comparison, By Indication. 130
11.4. Thailand Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 130
       11.4.1. Revenue (US$ Mn) Comparison, By Test Type. 130
       11.4.2. Revenue (US$ Mn) Comparison, By End User. 131
       11.4.3. Revenue (US$ Mn) Comparison, By Indication. 132
11.5. Singapore Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 133
       11.5.1. Revenue (US$ Mn) Comparison, By Test Type. 133
       11.5.2. Revenue (US$ Mn) Comparison, By End User. 134
       11.5.3. Revenue (US$ Mn) Comparison, By Indication. 135
11.6. Australia Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 136
       11.6.1. Revenue (US$ Mn) Comparison, By Test Type. 136
       11.6.2. Revenue (US$ Mn) Comparison, By End User. 137
       11.6.3. Revenue (US$ Mn) Comparison, By Indication. 137

Chapter 12. MEA Lung Cancer Diagnostics Market Analysis and Forecast, By Country, 2012-2022. 139
12.1. GCC Countries Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 139
       12.1.1. Revenue (US$ Mn) Comparison, By Test Type. 139
       12.1.2. Revenue (US$ Mn) Comparison, By End User. 140
       12.1.3. Revenue (US$ Mn) Comparison, By Indication. 141
12.2. South Africa Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 141
       12.2.1. Revenue (US$ Mn) Comparison, By Test Type. 141
       12.2.2. Revenue (US$ Mn) Comparison, By End User. 142
       12.2.3. Revenue (US$ Mn) Comparison, By Indication. 143
12.3. Nigeria Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 144
       12.3.1. Revenue (US$ Mn) Comparison, By Test Type. 144
       12.3.2. Revenue (US$ Mn) Comparison, By End User. 145
       12.3.3. Revenue (US$ Mn) Comparison, By Indication. 146
12.4. Israel Lung Cancer Diagnostics Market Size and Forecast, 2012-2022. 146
       12.4.1. Revenue (US$ Mn) Comparison, By Test Type. 146
       12.4.2. Revenue (US$ Mn) Comparison, By End User. 147
       12.4.3. Revenue (US$ Mn) Comparison, By Indication. 148

Chapter 13. Global Lung Cancer Diagnostics Market Company/Manufactures/Distributors/Suppliers Profile and Revenue Projections. 150
13.1. Illumina, Inc.. 150
       13.1.1. Company Overview. 150
       13.1.2. Product Overview. 151
       13.1.3. Key Financials. 151
       13.1.4. Key Developments. 151
       13.1.5. SWOT Analysis. 151
13.2. Abbott Laboratories. 153
       13.2.1. Company Overview. 153
       13.2.2. Product Overview. 153
       13.2.3. Key Financials. 153
       13.2.4. Key Developments. 154
       13.2.5. SWOT Analysis. 154
13.3. Thermo Fisher Scientific, Inc. 155
       13.3.1. Company Overview. 155
       13.3.2. Product Overview. 155
       13.3.3. Key Financials. 155
       13.3.4. Key Developments. 156
       13.3.5. SWOT Analysis. 156
13.4. QIAGEN N.V.. 157
       13.4.1. Company Overview. 157
       13.4.2. Product Overview. 157
       13.4.3. Key Financials. 158
13.5. Quest Diagnostics Incorporated. 159
       13.5.1. Company Overview. 159
       13.5.2. Product Overview. 159
       13.5.3. Key Financials. 159
       13.5.4. SWOT Analysis. 160
13.6. NeoGenomics Laboratories, Inc.. 162
       13.6.1. Company Overview. 162
       13.6.2. Key Financials. 162
13.7. NanoString Technologies Inc. 163
       13.7.1. Company Overview. 163
       13.7.2. Product Overview. 163
       13.7.3. Key Financials. 164
13.8. Myriad Genetics Inc. 165
       13.8.1. Company Overview. 165
       13.8.2. Product Overview. 165
       13.8.3. Key Financials. 166
       13.8.4. SWOT Analysis. 166
13.9. Roche Holding AG.. 169
       13.9.1. Company Overview. 169
       13.9.2. Product Overview. 169
       13.9.3. Key Financials. 170
       13.9.4. Key Developments. 170
       13.9.5. SWOT Analysis. 170
13.10. Danaher Corporation. 174
       13.10.1. Company Overview. 174
       13.10.2. Product Overview. 174
       13.10.3. Key Financials. 175
       13.10.4. Key Developments. 175
       13.10.5. SWOT Analysis. 175

Fact.MR offers custom research services that help clients to get specific research solutions

We are committed towards customer satisfaction and quality service.


Our Clients

Malaysian Cocoa Board
Dunlop International Europe Ltd
Roland Berger
Superior Essex
Commscope
Deloitte

Fact.MR in Media

Lung Cancer Diagnostics Market Forecast, Trend Analysis & Competition Tracking: Global Market insights 2017 to 2022